Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Lentzsch on How Patient Age Informs Treatment Decisions in Multiple Myeloma

November 12th 2021

Suzanne Lentzsch, MD, discusses how patient age informs treatment decisions in multiple myeloma.

Management of Patients with RRMM

November 12th 2021

Kenneth Shain, MD, PhD discusses multiple myeloma disease measurement, management, and personalization of treatment going forward.

Emerging Therapies in RRMM

November 12th 2021

Dr Kenneth Shain, a multiple myeloma expert, discusses emerging therapies with newer mechanisms of action for patients with RRMM.

PORT Trial

November 12th 2021

Multiple myeloma expert Dr Kenneth Shain discusses the PORT study comparing central vs peripheral administration of melphalan flufenamide.

OCEAN Trial

November 12th 2021

Kenneth Shain, MD, PhD reviews phase 3 OCEAN study design and safety and efficacy data from patients with RRMM treated with melphalan flufenamide + dexamethasone doublet or pomalidomide + dexamethasone.

Melphalan flufenamide

November 12th 2021

Multiple myeloma expert Dr Kenneth Shain discusses mechanism of action of melphalan flufenamide and the advantage it might offer to fight cancer cells.

Relapsed/Refractory Multiple Myeloma Landscape

November 12th 2021

Kenneth Shain, MD, PhD provides an overview of recent advances in the treatment of relapsed and refractory multiple myeloma.

Experts Talk Through Exciting T-Cell Therapies in Multiple Myeloma

November 11th 2021

Although BCMA-directed CAR T-cell therapy has shown early and deep responses in patients with relapsed/refractory multiple myeloma, there is much more to learn about optimal cytokine release syndrome and neurotoxicity management and treatment sequencing, particularly as off-the-shelf T-cell therapies, bispecific antibodies, and non–BCMA-directed therapies become available.

Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

November 10th 2021

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.

Dr. Dholaria on Patient Characteristics in the MagnetisMM-1 Trial in Multiple Myeloma

October 29th 2021

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Dr. Cohen on the Safety Profile of Cilta-Cel in Multiple Myeloma

October 28th 2021

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Dr. Brayer on the Promise of BiTEs in Multiple Myeloma

October 27th 2021

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

Research Underscores the Need for Serological Testing After COVID-19 Vaccination in Multiple Myeloma

October 26th 2021

A proportion of patients with multiple myeloma receiving CD38-directed and BCMA-directed therapies had a lack of T-cell responses and an absence of anti–SARS-CoV-2 Spike antibodies following SARS-CoV-2 vaccination, underscoring the need for serological testing after vaccination to identify these patients.

Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple Myeloma

October 26th 2021

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

October 25th 2021

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Shah on the Potential Utility of NK Cells in Multiple Myeloma

October 25th 2021

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States

October 22nd 2021

Oncopeptides AB has made the decision to withdraw the indication of melphalan flufenamide in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.

Dr. Hansen on the Utilization of BCMA-Directed Therapy in Multiple Myeloma

October 21st 2021

Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.

Dr. Brayer on the Emergence of BiTEs and Bispecific Antibodies in Multiple Myeloma

October 21st 2021

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Dr. Ghobrial on Future Efforts to Prevent the Development of Multiple Myeloma

October 20th 2021

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma.